Featured News
PPMD Invests $500,000 in Myosana Therapeutics to Advance Non-Viral Gene Therapy Platform
Parent Project Muscular Dystrophy is excited to announce a $500,000 programmatic investment in Myosana Therapeutics, Inc. (Myosana) to support the company’s continuing development and translation of a non-viral gene therapy delivery platform aiming to slow skeletal muscle degeneration and heart...
Are You Interested in Our Work?